Davide Ruggero
Co-Founder and Member of Clinical & Scientific Advisory BoardDr. Davide Ruggero, Ph.D. is a Member of Scientific Advisory Board at HTG Molecular Diagnostics, Inc. Dr. Ruggero is Co-Founder of eFFECTOR Therapeutics, Inc. and serves as its Member of Clinical & Scientific Advisory Board. Dr. Ruggero served as Member of Scientific Advisory Board at Hexagon Bio, Inc until 2024. Dr. Ruggero joined the University of California, San Francisco in July 2007 and serves as Associate Professor of Urology and member of he Helen Diller Family Comprehensive Cancer Center and the Multiple Myeloma Translational Initiative at UCSF. He is holder of the Helen Diller Family Endowed Chair in Basic Research and a pioneer in the field of translation control and cancer. He served as Assistant Professor in the Department of Human Genetics at the Fox Chase Cancer Center in Philadelphia. The implications of his research results are applied to designing a new generation of cancer therapeutic agents that specifically modulate the cancer cellular proteome at a post-genomic level. Dr. Ruggero has received noteworthy funding to support his groundbreaking cancer research. During his graduate and postdoctoral training he was awarded an Enichem Society fellowship and an American-Italian Cancer Foundation fellowship. As a senior post-doctoral fellow, Dr. Ruggero was one of two candidates, out of more than 400, to receive Memorial Sloan-Kettering Cancer Center’s Outstanding Research Fellow Award. In 2005, Dr. Ruggero received the prestigious V-Scholar Foundation’s Award for Cancer Research for his work on deregulations in protein synthesis during lymphomagenesis. He is also the recipient of the 2008 Gertrude B. Elion Cancer Research Award from the American Association for Cancer Research that acknowledges the outstanding achievements of one junior faculty in the country toward cancer research. Most recently, Dr. Ruggero was a recipient of the 2010 Leukemia & Lymphoma Society Scholar Award. He was an organizer of the first American Association for Cancer Research (AACR) Special Conference on Translation and Cancer in 2010. He is a co-organizer of the prestigious AACR Frontiers in Basic Cancer Research conference. Dr. Ruggero received his B.S. degree in Biology and his Ph.D. in Molecular and Cellular Biology from the University of Rome La Sapienza, Italy.
Positions
- Company NameeFFECTOR Therapeutics, Inc.Stock CodeEFTRPositionCo-Founder and Member of Clinical & Scientific Advisory Board
